Fairmount Funds Management, Director: Viridian Therapeutics, Inc.\DE VRDN Buy · Filed 05/13

Trade details

Type: Insider buy
Amount: $19,999,990
Shares · price: 1,176,470 sh · $17.00 a share
Held after: 5,090,928 sh
Stock: Viridian Therapeutics, Inc.\DE VRDN
Person: Fairmount Funds ManagementDirector
Trade date: 26/05/11
Filed: 26/05/13
Days to filing: 2 days

First buy since 2023

Insiders buying this week: 3 insiders
Holding change: +30.1%

Viridian Therapeutics, Inc.\DE trades, last 26 weeks

What else happened in Viridian Therapeutics, Inc.\DE around then

Filed or reported within 30 days of the trade day · 04/11~06/10

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31
Fairmount Funds ManagementDirector
Planned saleCogent Biosciences
Planned sale
Cogent Biosciences
COGT
$242.6M
7,000,000 sh
$242.6M
Filed 03/31
Traded 03/31